Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Perphenazine
Drug ID BADD_D01743
Description An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Indications and Usage For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Marketing Status approved
ATC Code N05AB03
DrugBank ID DB00850
KEGG ID D00503
MeSH ID D010546
PubChem ID 4748
TTD Drug ID D02HED
NDC Product Code 42973-165; 51407-697; 68084-607; 68382-592; 0781-8049; 23155-800; 23155-802; 51407-694; 70518-0710; 70518-2639; 70518-3106; 0904-6599; 63629-2248; 63629-2249; 63629-2250; 70518-0940; 70518-2985; 70518-3257; 70771-1042; 64980-290; 70518-0458; 70518-0731; 70518-1739; 70518-3108; 0591-4103; 0781-8047; 52536-164; 64980-291; 64980-292; 64980-293; 68382-593; 70518-1125; 71205-842; 0591-4102; 0603-5060; 0603-5061; 0904-6600; 52536-168; 63629-2251; 63629-2253; 70518-3121; 71205-843; 23155-801; 52536-162; 52536-170; 68084-602; 70771-1041; 71205-844; 0591-4101; 23155-799; 53808-1124; 70518-3033; 0904-6601; 46204-0003; 51407-696; 63629-2252; 68382-591; 70771-1044; 71205-841; 0603-5062; 0603-5063; 0781-8046; 0781-8048; 0591-4104; 68382-594; 70518-2890; 70771-1043; 65372-1191; 51407-695
UNII FTA7XXY4EZ
Synonyms Perphenazine | Perfenazine | Chlorpiprazine | Trilafon
Chemical Information
Molecular Formula C21H26ClN3OS
CAS Registry Number 58-39-9
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Neurogenic bladder20.03.03.001; 17.10.01.002--Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Night blindness06.02.10.010; 14.12.03.001--
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Opisthotonus17.01.03.005--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Polyuria20.02.03.002--Not Available
Pregnancy test false positive13.10.05.003--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Retinal disorder06.08.03.005--Not Available
Retinal pigmentation06.09.03.008--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin hyperpigmentation23.05.01.003--
Somnolence19.02.05.003; 17.02.04.006--
Sudden death08.04.01.003; 02.03.04.013--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages